Table 2.
Comparison of demographic and clinical characteristics among patients who experienced a complication within 30 days of the final stage of IPAA surgery for ulcerative colitis and patients who did not.
| No complications within 30 d (n = 111) | Complications within 30 d (n = 66) | P value | |
|---|---|---|---|
| Female | 47 (42) | 26 (39) | .700 |
| Race/ethnicity | .198 | ||
| Black or African American | 6 (5) | 8 (12) | |
| Hispanic | 4 (4) | 1 (2) | .417 |
| White | 95 (86) | 55 (83) | |
| Other | 10 (9) | 3 (5) | |
| Age at IPAA, y | 38.2 (27.6-55.0) | 43.4 (32.4-50.6) | .298 |
| Body mass index at time of IPAA | .156 | ||
| Underweight | 4 (4) | 4 (6) | |
| Normal | 51 (48) | 24 (38) | |
| Overweight | 35 (33) | 18 (28) | |
| Obese | 16 (15) | 18 (28) | |
| Disease extent prior to surgerya | .003 | ||
| Proctitis | 1 (1) | 4 (7) | |
| Left-sided | 28 (29) | 5 (9) | |
| Extensive colitis | 67 (70) | 48 (84) | |
| Indication for surgery | .866 | ||
| Medically refractory colitis | 85 (77) | 54 (82) | |
| Dysplasia/colorectal cancer | 10 (9) | 4 (6) | |
| Other | 12 (11) | 6 (9) | |
| Medically refractory disease and dysplasia/colorectal cancer | 3 (3) | 2 (3) | |
| Number of stages in surgery | .018 | ||
| 1 | 6 (5) | 0 (0) | |
| 2 | 24 (22) | 19 (29) | |
| Modified 2 | 34 (31) | 30 (45) | |
| 3 | 47 (42) | 17 (26) | |
| Delayed pouch creationb | 81 (77) | 47 (71) | .384 |
| Time between colectomy and final stage of surgery, dc | 138 (57-259) | 134 (69-239) | .883 |
| Smoking status at the time of colectomy | .006 | ||
| Current | 1 (1) | 3 (5) | |
| Former | 23 (21) | 23 (39) | |
| Never | 86 (78) | 37 (56) | |
| Primary sclerosing cholangitis | 8 (7) | 4 (6) | .769 |
| Extraintestinal manifestations of IBD | 109 (98) | 63 (95) | .287 |
| Pathology findings at the time of colectomy | |||
| Granulomas | 5 (5) | 2 (3) | 1.000 |
| Ileitis | 17 (15) | 10 (15) | .978 |
| Transmural inflammation | 12 (11) | 11 (17) | .263 |
| NSAIDs at the time of IPAA | 27 (25) | 22 (34) | .211 |
| Therapy in 30 d prior to final stage of IPAA surgery | |||
| Oral steroids | 20 (18) | 13 (20) | .745 |
| Topical steroids | 3 (3) | 3 (5) | .500 |
| Oral aminosalicylate | 6 (5) | 5 (8) | .556 |
| Topical aminosalicylate | 3 (3) | 2 (3) | 1.000 |
| Thiopurine (azathioprine or mercaptopurine) | 2 (2) | 1 (2) | 1.000 |
| Methotrexate | 1 (1) | 0 (0) | 1.000 |
| Tofacitinib | 4 (4) | 2 (3) | 1.000 |
| Anti-TNF monotherapy | 3 (3) | 2 (3) | 1.000 |
| Ustekinumab | 1 (1) | 0 (0) | 1.000 |
| Vedolizumab | 1 (1) | 1 (2) | 1.000 |
Values are n (%) or median (interquartile range).
Abbreviations: anti-TNF, anti-tumor necrosis factor α; IBD, inflammatory bowel disease; IPAA, ileal pouch–anal anastomosis; NSAID, nonsteroidal anti-inflammatory drug.
aDisease extent at the time of surgery unknown for 24 patients.
bDelayed pouch creation defined as a modified 2-stage or 3-stage approach to IPAA.
cTime between colectomy and final stage of surgery evaluated among all patients with a 2-stage, modified 2-stage1 or 3-stage approach to IPAA.